Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.
Several genome-wide association studies (GWAS) have been conducted to identify the common single nucleotide polymorphisms (SNPs) that influence the risk of prostate cancer. It was hypothesized that some prostate cancer-associated SNPs might relate to the clinical outcomes in patients treated for pro...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3402522?pdf=render |
| _version_ | 1818039448361762816 |
|---|---|
| author | Shu-Pin Huang Bo-Ying Bao Tzyh-Chyuan Hour Chao-Yuan Huang Chia-Cheng Yu Chia-Chu Liu Yung-Chin Lee Chun-Nung Huang Jiunn-Bey Pao Chun-Hsiung Huang |
| author_facet | Shu-Pin Huang Bo-Ying Bao Tzyh-Chyuan Hour Chao-Yuan Huang Chia-Cheng Yu Chia-Chu Liu Yung-Chin Lee Chun-Nung Huang Jiunn-Bey Pao Chun-Hsiung Huang |
| author_sort | Shu-Pin Huang |
| collection | DOAJ |
| description | Several genome-wide association studies (GWAS) have been conducted to identify the common single nucleotide polymorphisms (SNPs) that influence the risk of prostate cancer. It was hypothesized that some prostate cancer-associated SNPs might relate to the clinical outcomes in patients treated for prostate cancer using androgen-deprivation therapy (ADT). A cohort of 601 patients who have received ADT for prostate cancer was genotyped for 29 SNPs that have been associated with prostate cancer in Cancer Genetic Markers of Susceptibility GWAS, and within the genes that have been implicated in cancer. Prognostic significance of these SNPs on the disease progression, prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) after ADT were assessed by Kaplan-Meier analysis and Cox regression model. Three SNPs, namely CASP3 rs4862396, BMP5 rs3734444 and IRS2 rs7986346, were found to be closely associated with the ACM (P≤0.042), and BMP5 rs3734444 and IRS2 rs7986346 were also noted to be significantly related to the PCSM (P≤0.032) after adjusting for the known clinicopathologic predictors. Moreover, patients carrying a greater number of unfavorable genotypes at the loci of interest had a shorter time to ACM and PCSM during ADT (P for trend <0.001). Our results suggest that CASP3 rs4862396, BMP5 rs3734444 and IRS2 rs7986346 may affect the survival in patients after ADT for prostate cancer, and the analysis of these SNPs can help identify patients at higher risk of poor outcome. |
| first_indexed | 2024-12-10T07:58:48Z |
| format | Article |
| id | doaj.art-9a591ef67be342f6acbf326dfe96c1f5 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T07:58:48Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9a591ef67be342f6acbf326dfe96c1f52022-12-22T01:56:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0177e4121910.1371/journal.pone.0041219Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.Shu-Pin HuangBo-Ying BaoTzyh-Chyuan HourChao-Yuan HuangChia-Cheng YuChia-Chu LiuYung-Chin LeeChun-Nung HuangJiunn-Bey PaoChun-Hsiung HuangSeveral genome-wide association studies (GWAS) have been conducted to identify the common single nucleotide polymorphisms (SNPs) that influence the risk of prostate cancer. It was hypothesized that some prostate cancer-associated SNPs might relate to the clinical outcomes in patients treated for prostate cancer using androgen-deprivation therapy (ADT). A cohort of 601 patients who have received ADT for prostate cancer was genotyped for 29 SNPs that have been associated with prostate cancer in Cancer Genetic Markers of Susceptibility GWAS, and within the genes that have been implicated in cancer. Prognostic significance of these SNPs on the disease progression, prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) after ADT were assessed by Kaplan-Meier analysis and Cox regression model. Three SNPs, namely CASP3 rs4862396, BMP5 rs3734444 and IRS2 rs7986346, were found to be closely associated with the ACM (P≤0.042), and BMP5 rs3734444 and IRS2 rs7986346 were also noted to be significantly related to the PCSM (P≤0.032) after adjusting for the known clinicopathologic predictors. Moreover, patients carrying a greater number of unfavorable genotypes at the loci of interest had a shorter time to ACM and PCSM during ADT (P for trend <0.001). Our results suggest that CASP3 rs4862396, BMP5 rs3734444 and IRS2 rs7986346 may affect the survival in patients after ADT for prostate cancer, and the analysis of these SNPs can help identify patients at higher risk of poor outcome.http://europepmc.org/articles/PMC3402522?pdf=render |
| spellingShingle | Shu-Pin Huang Bo-Ying Bao Tzyh-Chyuan Hour Chao-Yuan Huang Chia-Cheng Yu Chia-Chu Liu Yung-Chin Lee Chun-Nung Huang Jiunn-Bey Pao Chun-Hsiung Huang Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. PLoS ONE |
| title | Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. |
| title_full | Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. |
| title_fullStr | Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. |
| title_full_unstemmed | Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. |
| title_short | Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. |
| title_sort | genetic variants in casp3 bmp5 and irs2 genes may influence survival in prostate cancer patients receiving androgen deprivation therapy |
| url | http://europepmc.org/articles/PMC3402522?pdf=render |
| work_keys_str_mv | AT shupinhuang geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT boyingbao geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT tzyhchyuanhour geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT chaoyuanhuang geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT chiachengyu geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT chiachuliu geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT yungchinlee geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT chunnunghuang geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT jiunnbeypao geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy AT chunhsiunghuang geneticvariantsincasp3bmp5andirs2genesmayinfluencesurvivalinprostatecancerpatientsreceivingandrogendeprivationtherapy |